Lancet diabetes and endocrinology.

PubMed: Background Diabetes is a major risk factor for erectile dysfunction, however, the effect of GLP-1 receptor agonists on erectile dysfunction is unknown.

We aimed to assess the incidence, prevalence, and progression of erectile dysfunction in men treated with dulaglutide compared with placebo, and to determine whether dulaglutide's effect on erectile dysfunction was consistent with its effect on other diabetes-related outcomes.

Men and women aged older than 50 years with type 2 diabetes, who had either a previous cardiovascular event or cardiovascular risk factors, were randomly assigned to receive either dulaglutide or placebo. Participating men were offered the opportunity to complete the standardised International Index of Erectile Function IIEF questionnaire at baseline, 2 years, 5 years, and study end.

We did an exploratory analysis, in which we included participants who completed a baseline and at least 1 follow-up IIEF questionnaire.

The primary outcome for these analyses was the first occurrence of moderate or severe erectile dysfunction following randomisation, assessed by the erectile function subscores on IIEF.

Interpretation Long-term use of dulaglutide might reduce the incidence of moderate or severe erectile dysfunction in men with type 2 diabetes.

Funding Eli Lilly and Company. Copyright c Elsevier Ltd. All rights reserved.